MTM(SH:688029)2024-10-29 10:38Financial Performance - The company's operating revenue for Q3 2024 reached ¥678,602,151.95, representing a year-over-year increase of 13.44%[2] - Net profit attributable to shareholders was ¥140,630,694.66, reflecting a 15.06% increase compared to the same period last year[2] - The basic earnings per share for the quarter was ¥0.75, up 15.38% year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥139,936,897.60, up 17.82% year-over-year[2] - The company reported a net profit of approximately CNY 1.56 billion for the first three quarters of 2024, compared to CNY 1.39 billion for the same period in 2023, reflecting an increase of about 12.06%[13] - Net profit for Q3 2024 was CNY 464,032,872.96, representing a 17.4% increase from CNY 395,076,681.45 in the same quarter last year[15] - Basic and diluted earnings per share for Q3 2024 were both CNY 2.41, compared to CNY 2.06 in Q3 2023, marking an increase of 17%[16] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥4,566,598,060.14, an increase of 3.96% from the end of the previous year[3] - As of September 30, 2024, the total assets of Nanwei Medical Technology Co., Ltd. reached approximately CNY 4.57 billion, an increase from CNY 4.39 billion at the end of 2023, reflecting a growth of about 3.77%[11] - The company's current assets totaled approximately CNY 3.29 billion, slightly down from CNY 3.29 billion at the end of 2023, indicating a marginal decrease of 0.02%[10] - The total liabilities of the company amounted to approximately CNY 764.31 million, an increase from CNY 722.51 million, indicating a rise of about 5.79%[12] - The equity attributable to shareholders increased to approximately CNY 3.73 billion from CNY 3.61 billion, showing a growth of about 3.31%[12] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥381,656,637.85, showing a 6.26% increase compared to the same period last year[2] - Cash flow from operating activities generated CNY 381,656,637.85, slightly up from CNY 359,177,957.50 in the previous year[17] - Cash inflow from operating activities totaled CNY 2,109,854,672.77, an increase from CNY 1,791,077,407.19 in the previous year[17] - The net cash flow from investment activities was -55,315,049.28 CNY, a significant improvement from -1,529,252,872.06 CNY in the same period last year[19] - Total cash inflow from investment activities reached 2,314,666,583.30 CNY, compared to 997,115,514.58 CNY in Q3 2023, indicating a 132.5% increase[19] - Cash outflow for investment activities was 2,369,981,632.58 CNY, down from 2,526,368,386.64 CNY year-over-year, reflecting a decrease of 6.2%[19] - The net cash flow from financing activities was -246,597,988.32 CNY, worsening from -72,888,320.21 CNY in the previous year[19] - Cash and cash equivalents at the end of Q3 2024 totaled 1,281,557,227.56 CNY, up from 660,725,878.76 CNY in Q3 2023, marking a 94.0% increase[19] Research and Development - Research and development expenses totaled ¥41,987,560.64, which is 6.19% of operating revenue, marking a 23.75% increase in R&D investment[3] - Research and development expenses for Q3 2024 totaled CNY 111,568,259.50, an increase of 8.9% from CNY 102,602,589.38 in Q3 2023[14] Market Expansion and Investments - The company obtained a total of 34 initial registration certificates and 22 change registration certificates for its products across 15 countries, including China, the USA, Germany, and Brazil during the reporting period[8] - The company plans to continue expanding its market presence and invest in new product development to drive future growth[11] - The company has increased its long-term investments, with long-term equity investments rising to approximately CNY 56.26 million from CNY 49.71 million, indicating a growth of about 13.06%[11] Operating Costs - Total operating costs amounted to CNY 1,467,685,015.45, up from CNY 1,293,258,893.85, reflecting a year-over-year increase of 13.5%[14] - Sales expenses rose to CNY 465,159,798.73, compared to CNY 382,701,595.11, indicating a year-over-year increase of 21.5%[14]